閭雯娟,游佳,蔣繼澤,李明
靜脈復(fù)合麻醉對(duì)玻璃體切割術(shù)的安全性及滿意度研究
閭雯娟1,游佳2,蔣繼澤1,李明1
1.新疆四七四醫(yī)院眼科,新疆烏魯木齊 830000;2.新疆伊犁州友誼醫(yī)院心內(nèi)科,新疆伊寧 835000
探討右美托咪定靜脈復(fù)合麻醉在玻璃體切割術(shù)中的安全性及對(duì)患者和醫(yī)生滿意度的影響。選取2022年1月至6月于新疆四七四醫(yī)院擬行玻璃體切割術(shù)的患者269例,根據(jù)隨機(jī)數(shù)字表法將其分成右美托咪定組(=143)和生理鹽水組(=126)。比較兩組患者的一般資料、血流動(dòng)力學(xué)指標(biāo)、Ramsay鎮(zhèn)靜評(píng)分、患者和手術(shù)醫(yī)生對(duì)麻醉的滿意度。右美托咪定組患者鎮(zhèn)靜恰當(dāng)?shù)谋壤@著高于生理鹽水組(<0.01)。右美托咪定組患者及手術(shù)醫(yī)生對(duì)術(shù)中麻醉的滿意度均顯著高于生理鹽水組(<0.05)。手術(shù)開(kāi)始后10min和30min、手術(shù)結(jié)束時(shí),右美托咪定組患者的心率、呼吸頻率、平均動(dòng)脈壓均顯著低于同期生理鹽水組(<0.05),兩組患者的血氧飽和度比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(>0.05)。兩組患者的惡心、嘔吐、呼吸抑制等不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義(>0.05)。右美托咪定靜脈復(fù)合麻醉是玻璃體切割術(shù)安全可靠的鎮(zhèn)靜方法,可提高患者和手術(shù)醫(yī)生的滿意度,無(wú)呼吸道并發(fā)癥。
右美托咪定;靜脈復(fù)合麻醉;玻璃體切割術(shù);安全性;滿意度
隨著科學(xué)技術(shù)的發(fā)展,玻璃體切割術(shù)已成為眼底病常用的治療方法,主要用于治療糖尿病性視網(wǎng)膜病變、增殖性玻璃體視網(wǎng)膜病變等,但眼底病患者多為中老年人,常合并多種全身系統(tǒng)性疾病,全身麻醉的術(shù)中及術(shù)后風(fēng)險(xiǎn)不可忽視,因此,局部麻醉在眼科手術(shù)中的應(yīng)用越來(lái)越廣泛。研究顯示,眼部局部麻醉在短時(shí)間內(nèi)即可達(dá)到較好的鎮(zhèn)痛效果,且術(shù)后恢復(fù)快,術(shù)后心肺并發(fā)癥和術(shù)后惡心嘔吐的發(fā)生率較低[1]。其中,球周麻醉被認(rèn)為是玻璃體切割術(shù)的安全麻醉方式[2]。局部麻醉下的玻璃體切割術(shù),由于患者清醒,可感到疼痛、恐懼和焦慮,對(duì)手術(shù)的體驗(yàn)感不佳,降低患者對(duì)手術(shù)的配合度,導(dǎo)致手術(shù)風(fēng)險(xiǎn)增大,患者和手術(shù)醫(yī)生對(duì)手術(shù)的滿意度下降,最終影響手術(shù)效果。本研究旨在觀察右美托咪定靜脈復(fù)合麻醉對(duì)玻璃體切割術(shù)的安全性及患者和手術(shù)醫(yī)生的滿意度,現(xiàn)將結(jié)果報(bào)道如下。
選取2022年1月至6月于新疆四七四醫(yī)院擬行玻璃體切割術(shù)的患者269例,根據(jù)隨機(jī)數(shù)字表法將其分成右美托咪定組(=143)和生理鹽水組(=126)。納入標(biāo)準(zhǔn):①年齡>18歲;②需進(jìn)行玻璃體切割術(shù);③單眼患病。排除標(biāo)準(zhǔn):①長(zhǎng)期使用大劑量鎮(zhèn)靜藥者;②合并中樞神經(jīng)系統(tǒng)疾病者;③無(wú)法實(shí)施局部麻醉者。本研究經(jīng)新疆四七四醫(yī)院倫理委員會(huì)批準(zhǔn)(倫理審批號(hào):20210307011),所有患者均簽署知情同意書。
患者術(shù)前開(kāi)放外周靜脈通路,低流量吸氧,術(shù)中監(jiān)測(cè)并記錄患者的血流動(dòng)力學(xué)變化。右美托咪定組患者給予4μg/ml的右美托咪定(批準(zhǔn)文號(hào):國(guó)藥準(zhǔn)字H20183219,生產(chǎn)單位:揚(yáng)子江藥業(yè)集團(tuán)有限公司,規(guī)格:2ml:0.2mg),以負(fù)荷量1μg/ml靜脈泵入,10min后以0.2~0.7μg/(kg·h)持續(xù)輸注。術(shù)畢前10min停藥。生理鹽水組患者采用相同方法泵注等容量的生理鹽水。兩組患者均在球周麻醉下完成玻璃體切割術(shù)。
采用Ramsay鎮(zhèn)靜評(píng)分評(píng)定患者的麻醉效果:1分為不安靜、躁動(dòng);2分為安靜配合;3分為嗜睡但能配合指令;4分為睡眠狀態(tài)但易被喚醒;5分為睡眠狀態(tài)但不易被喚醒,反應(yīng)遲鈍;6分為深睡眠狀態(tài)不能被喚醒。其中,1分為鎮(zhèn)靜不足,2~4分為鎮(zhèn)靜恰當(dāng),5~6分為鎮(zhèn)靜過(guò)度。術(shù)后采用Likert 5級(jí)評(píng)分法評(píng)估患者及手術(shù)醫(yī)生對(duì)麻醉效果的滿意度。
監(jiān)測(cè)并記錄兩組患者麻醉前(T0)、手術(shù)開(kāi)始后10min(T10)、手術(shù)開(kāi)始后30min(T30)及手術(shù)結(jié)束時(shí)(Tend)各時(shí)間點(diǎn)的心率(heart rate,HR)、呼吸頻率(respiratory rate,RR)、平均動(dòng)脈壓(mean arterial pressure,MAP)、血氧飽和度(blood oxygen saturation,SO2)及全身不良反應(yīng)。
兩組患者的年齡、性別、體質(zhì)量、術(shù)前MAP、術(shù)前HR、手術(shù)時(shí)間比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(>0.05),見(jiàn)表1。
右美托咪定組患者的鎮(zhèn)靜恰當(dāng)比例顯著高于生理鹽水組(=0.008),見(jiàn)表2。
右美托咪定組患者及手術(shù)醫(yī)生對(duì)術(shù)中麻醉的滿意度均顯著高于生理鹽水組(<0.05),見(jiàn)表3。
兩組患者T0時(shí)點(diǎn)的HR、MAP、RR、SO2比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(>0.05)。T10、T30、Tend時(shí)點(diǎn),右美托咪定組患者的HR、MAP、RR均顯著低于同期生理鹽水組(<0.05),兩組患者的SO2比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(>0.05),見(jiàn)表4。
兩組患者的惡心、嘔吐、呼吸抑制等不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義(>0.05)。
表1 兩組患者的一般資料比較
注:1mmHg=0.133kPa
表2 兩組患者的Ramsay鎮(zhèn)靜評(píng)分比較[n(%)]
表3 兩組患者及手術(shù)醫(yī)生的滿意度比較[n(%)]
表4 兩組患者不同時(shí)點(diǎn)的血流動(dòng)力學(xué)比較()
注:1mmHg=0.133kPa
傳統(tǒng)的局部麻醉主要包括球后麻醉和球周麻醉,具有手術(shù)風(fēng)險(xiǎn)小、疼痛緩解程度高、血流動(dòng)力學(xué)穩(wěn)定性好、不良反應(yīng)少等優(yōu)點(diǎn)[3],但均不能做到完全無(wú)痛,只能使疼痛控制在患者可耐受的范圍內(nèi),手術(shù)時(shí)的機(jī)械刺激仍可引起患者緊張?jiān)陝?dòng),甚至使血流動(dòng)力學(xué)波動(dòng)。尤其是球后麻醉還存在刺穿眼球、球后出血、視神經(jīng)損傷等嚴(yán)重并發(fā)癥。
眼部手術(shù)精度高,如果術(shù)中鎮(zhèn)痛效果不滿意,不僅給患者帶來(lái)生理上的痛苦和心理上的創(chuàng)傷,還會(huì)降低患者的配合度,增加手術(shù)難度,進(jìn)而影響手術(shù)完成的質(zhì)量和速度。為解決這一問(wèn)題,一些鎮(zhèn)靜藥物開(kāi)始逐步應(yīng)用于玻璃體切割術(shù)。但也帶來(lái)一些不可避免的副作用,包括肺通氣不足、過(guò)度鎮(zhèn)靜、定向障礙干擾術(shù)中患者配合等[4]。右美托咪定是一種高選擇性的α2腎上腺素能受體激動(dòng)劑,可提供一種特殊的“清醒鎮(zhèn)靜”,彌補(bǔ)局部麻醉手術(shù)的不足,目前常用于神經(jīng)外科手術(shù),并取得良好效果[5-6]。
手術(shù)麻醉的宗旨是確?;颊叩陌踩?,并為外科醫(yī)生提供最佳的手術(shù)條件,而患者的肌肉松弛程度是外科醫(yī)生對(duì)手術(shù)滿意度的重要因素。右美托咪定產(chǎn)生的睡眠狀態(tài)可很好地達(dá)到這個(gè)目標(biāo),同時(shí)因患者易被喚醒,認(rèn)知和合作能力沒(méi)有下降,在有需要的時(shí)候可配合手術(shù),之后短時(shí)間內(nèi)又可再次恢復(fù)到鎮(zhèn)靜狀態(tài)[7-9]。本研究中,所有患者均順利完成手術(shù),右美托咪定組患者和手術(shù)醫(yī)生對(duì)手術(shù)麻醉的滿意度明顯高于生理鹽水組,達(dá)到目標(biāo)鎮(zhèn)靜水平的患者明顯多于生理鹽水組,說(shuō)明在球周麻醉下玻璃體切割術(shù)中使用右美托咪定靜脈復(fù)合麻醉可取得較好的鎮(zhèn)靜麻醉效果,還可大幅度提高患者和手術(shù)醫(yī)生的滿意度,這種滿意度的提高可能與右美托咪定類似于自然睡眠的鎮(zhèn)靜作用有關(guān)。
雖然有報(bào)道稱使用右美托咪定后有低血壓和心動(dòng)過(guò)緩等不良反應(yīng),但仍認(rèn)為右美托咪定在需要覺(jué)醒鎮(zhèn)靜的手術(shù)中有較大優(yōu)勢(shì)[10-11]。本研究中兩組患者手術(shù)前均出現(xiàn)不同程度的HR和RR加快、MAP升高等生理指標(biāo)的變化,在手術(shù)開(kāi)始后生理鹽水組患者仍保持較高水平,而右美托咪定組患者的HR、RR、MAP均有所下降,且并未引起明顯心動(dòng)過(guò)緩或血壓降低。分析原因:術(shù)前HR、RR、MAP升高可能與手術(shù)前患者情緒緊張有關(guān),手術(shù)開(kāi)始后右美托咪定組患者血流動(dòng)力學(xué)指標(biāo)的平穩(wěn)下降與右美托咪定靜脈復(fù)合麻醉鎮(zhèn)靜有關(guān)。生理鹽水組患者術(shù)中很難進(jìn)入睡眠,故術(shù)中血壓、HR持續(xù)保持較高水平,這種變化增加合并基礎(chǔ)疾病高齡患者的心腦血管意外發(fā)生風(fēng)險(xiǎn)。研究顯示右美托咪定除穩(wěn)定血流動(dòng)力學(xué)外,還可改善左心室功能、減少心肌梗死面積,在一定程度上對(duì)心臟有保護(hù)作用[12-13]。既往研究也顯示右美托咪定不僅對(duì)心臟疾病患者和心臟外科手術(shù)具有良好的麻醉作用,且在非心臟的其他外科手術(shù)中,還可降低患者心血管意外的發(fā)生率[14-16]。本研究中所有患者均未發(fā)生與麻醉相關(guān)的心血管不良事件,同時(shí)也未發(fā)現(xiàn)有明顯的呼吸抑制,兩組患者各時(shí)點(diǎn)的SO2無(wú)明顯變化,這與既往研究結(jié)果相符合[9,17]。
綜上,右美托咪定靜脈復(fù)合麻醉是局部麻醉玻璃體切割術(shù)的一種安全有效的麻醉方式,臨床應(yīng)用時(shí)應(yīng)嚴(yán)格控制右美托咪定的劑量,密切關(guān)注血流動(dòng)力學(xué)指標(biāo)變化,避免不良事件發(fā)生。
[1] SINGH RB, KHERA T, LY V, et al. Ocular complications of perioperative anesthesia: A review[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(8): 2069–2083.
[2] CARVALHO B, JANTARADA C, AZEVEDO J, et al. Comparison of peribulbar block and general anaesthesia in mechanical vitrectomy: A prospective observational study[J]. Rev Esp Anestesiol Reanim (Engl Ed), 2020, 67(2): 63–67.
[3] ZHOU Y L, TONG Y, WANG Y X, et al. A prospective, randomised, double-masked comparison of local anaesthetic agents for vitrectomy[J]. Br J Ophthalmol, 2017, 101(8): 1016–1021.
[4] COTé G A, HOVIS R M, ANSSTAS M A, et al. Incidence of sedation-related complications with propofol use during advanced endoscopic procedures[J]. Clin Gastroenterol Hepatol, 2010, 8(2): 137–142.
[5] AFONSO J, REIS F. Dexmedetomidine: Current role in anesthesia and intensive care[J]. Rev Bras Anestesiol, 2012, 62(1): 118–133.
[6] TASBIHGOU S R, BARENDS C R M, ABSALOM A R. The role of dexmedetomidine in neurosurgery[J]. Best Pract Res Clin Anaesthesiol, 2021, 35(2): 221–229.
[7] COLIN P J, HANNIVOORT L N, ELEVELD D J, et al. Dexmedetomidine pharmacokinetic-pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation[J]. Br J Anaesth, 2017, 119(2): 200–210.
[8] GULDENMUND P, VANHAUDENHUYSE A, SANDERS R D, et al. Brain functional connectivity differentiates dexmedetomidine from propofol and natural sleep[J]. Br J Anaesth, 2017, 119(4): 674–684.
[9] WEERINK M A S, STRUYS M M R F, HANNIVOORT L N, et al. Clinical pharmacokinetics and pharmacodynamicsof dexmedetomidine[J]. Clin Pharmacokinet, 2017, 56(8): 893–913.
[10] LU Z. Dexmedetomidine is associated with intraoperativehypotension and may bring poor postoperative outcomes[J]. Int J Geriatr Psychiatry, 2021, 36(9): 1464.
[11] SUERO MOLINA E, SCHIPMANN S, MUELLER I, et al. Conscious sedation with dexmedetomidine compared with asleep-awake-asleep craniotomies in glioma surgery: An analysis of 180 patients[J]. J Neurosurg, 2018, 129(5): 1223–1230.
[12] 楊逸成, 陳貝兒, 葉凱雁, 等. 右美托咪定的心臟保護(hù)機(jī)制及其臨床應(yīng)用價(jià)值[J]. 中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào), 2022, 44(1): 130–135.
[13] HE L, HAO S, WANG Y, et al. Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction[J]. Biomed Pharmacother, 2019, 114: 108837.
[14] SRINIVAS D B, LAKSHMINARASIMHAIAH G. Comparison of subcutaneous dexmedetomidine versus clonidine as an adjuvant to spinal anesthesia: A randomized double blind control trial[J]. Local Reg Anesth, 2019, 12: 29–36.
[15] SUBRAMANIAM B, SHANKAR P, SHAEFI S, et al. Effect of intravenous acetaminophen vs placebo combined with propofol or dexmedetomidine on postoperative delirium among older patients following cardiac surgery: The DEXACET randomized clinical trial[J]. JAMA, 2019, 321(7): 686–696. .
[16] ORTMANN L A, KESHARY M, BISSELOU K S, et al. Association between postoperative dexmedetomidine use and arrhythmias in infants after cardiac surgery[J]. World J Pediatr Congenit Heart Surg, 2019, 10(4): 440–445.
[17] LIN N, VUTSKITS L, BEBAWY J F, et al. Perspectives on dexmedetomidine use for neurosurgical patients[J]. J Neurosurg Anesthesiol, 2019, 31(4): 366–377.
Study on the safety and satisfaction of combined intravenous anesthesia for vitrectomy
LYU Wenjuan, YOU Jia, JIANG Jize, LI Ming
1.Department of Ophthalmology, Xinjiang 474 Hospital, Urumqi 830000, Xinjiang, China; 2.Department of Cardiology, Xinjiang Yili Friendship Hospital, Yining 835000, Xinjiang, China
To investigate the safety of dexmedetomidine intravenous anesthesia in vitrectomy and the effect on the satisfaction of patients and doctors.A total of 269 patients who were to undergo vitrectomy in Xinjiang 474 Hospital from January to June 2022 were selected and divided into dexmedetomidine group (=143) and saline group (=126) according to random number table method. The general data, hemodynamic parameters, Ramsay sedation score, and the satisfaction of patients and surgeons with anesthesia were compared between the two groups.The proportion of patients with proper sedation in dexmedetomidine group was significantly higher than that in saline group (<0.01). The satisfaction of patients and surgeons in dexmedetomidine group was significantly higher than that in saline group (<0.05). 10 min and 30 min after operation and at the end of operation, the heart rate, respiratory rate, and mean arterial pressure in dexmedetomidine group were significantly lower than those in saline group (<0.05), and there was no statistically significant difference in blood oxygen saturation between the two groups (>0.05). There was no statistically significant difference in the incidence of adverse reactions such as nausea, vomiting, and respiratory depression between the two groups (>0.05).Dexmedetomidine intravenous anesthesia is a safe and reliable sedative method for vitrectomy, which can improve the satisfaction of patients and surgeons without respiratory complications.
Dexmedetomidine; Combined intravenous anesthesia; Vitrectomy; Safety; Satisfaction
R776.4
A
10.3969/j.issn.1673-9701.2023.25.017
閭雯娟,電子信箱:460376513@qq.com
(2022–11–02)
(2023–08–27)